Mechanism-based strategies including CAR-T and bispecific engagers offer options for rituximab-resistant primary membranous nephropathy
New Strategies Target Treatment Resistance in Membranous Nephropathy
This systematic review examines the multifactorial mechanisms of rituximab resistance in patients with primary membranous nephropathy. It id…
Researchers identify new ways to treat primary membranous nephropathy when standard rituximab treatments do not work.
Rituximab rechallenge caused severe hypersensitivity reaction in a patient with membranous nephropathy
A third Rituximab dose caused severe shock in a man with kidney disease
This case report describes a 52-year-old male with biopsy-proven primary membranous nephropathy who received a third 1 g infusion of rituxim…
A man with kidney disease developed life-threatening shock after a third Rituximab infusion, highlighting the need for careful monitoring an…
Narrative review discusses potential therapeutic roles of herbal compounds in membranous nephropathy
Ancient Herbs Could Protect Kidneys From Autoimmune Damage
This narrative review explores the potential therapeutic roles of specific herbal compounds, including icariin and astragaloside IV, for mem…
Scientists are finding new ways to use natural plant compounds to protect damaged kidney filters.
Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients
New Dosing Strategy Helps Kidney Disease Patients Who Didn’t Respond to Standard Treatment
This single-center retrospective cohort study evaluated 33 patients with refractory membranous nephropathy treated with a B-cell reconstitut…
For patients with a stubborn kidney disease who ran out of options, a smarter dosing strategy may offer a new path to recovery.
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases.
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
Review of Traditional Chinese Botanical Medicine in Membranous Nephropathy
A review examines traditional Chinese medicine for kidney condition known as membranous nephropathy
This narrative review examines the use of Traditional Chinese Botanical Medicine (CHMs) and their active metabolites for membranous nephropa…
Traditional Chinese botanical medicines show promise for treating membranous nephropathy, but this review found no proof of their safety or …
Rituximab with prednisone reduced proteinuria in Sjögren's syndrome-associated membranous nephropathy case
Rituximab treatment reduced kidney protein loss in one Sjögren's syndrome patient
A case report describes a 48-year-old female with primary Sjögren's syndrome and nephrotic-range proteinuria treated with prednisone and rit…
A 48-year-old woman with Sjögren's syndrome saw her kidney protein loss drop from 8.5 to 2.2 grams after receiving rituximab treatment.
Research across Nephritis
Related studies from across the Nephritis family.
Wiskott-Aldrich syndrome with IgA nephropathy requires early recognition and multidisciplinary management
Kidney and immune issues linked to rare blood disorders in a boy
This narrative review and case presentation describes a 10-year-old boy with Wiskott-Aldrich syndrome/X-linked thrombocytopenia and IgA neph…
A 10-year-old boy with rare blood disorders developed kidney disease, showing how these conditions can affect multiple organs.
Meta-Analysis Reveals Shared Genetic Loci in Pediatric Nephrotic Syndrome and IgA Nephropathy
Genetic clues link immune cells to pediatric kidney disease risks
A meta-analysis of GWAS data identified nine genome-wide significant loci for pediatric steroid-sensitive nephrotic syndrome and 19 pleiotro…
A large genetic analysis connects specific immune cell pathways to pediatric kidney conditions, offering new targets for future treatments.
Telitacicept reduces proteinuria in adults with IgA nephropathy in Phase 3 trial
New Drug Slashes Kidney Damage Risk in IgA Nephropathy Patients
This is an interim analysis of a Phase 3, multicenter, randomized, placebo-controlled trial in 318 adults with IgA nephropathy and persisten…
A targeted therapy reduced protein in urine by 55 percent more than placebo in people with IgA nephropathy, offering new hope for slowing ki…
Scoping review finds SGLT2 inhibitors show kidney protection in IgA nephropathy
Two major trials show kidney-protective effects for a specific IgA nephropathy group
This scoping review synthesizes evidence on SGLT2 inhibitors in IgA nephropathy.
Two large trials found kidney-protective effects for some IgA nephropathy patients taking SGLT2 inhibitors, while real-world data showed red…
Dyslipidemia linked to poorer renal survival in primary IgA nephropathy patients
High cholesterol linked to faster kidney failure in IgA nephropathy
This retrospective observational cohort study of 458 primary IgA nephropathy patients found that dyslipidemia was associated with poorer ren…
People with IgA nephropathy and high cholesterol face a higher risk of kidney failure, a new study finds.
Podocyte morphometrics correlate with albuminuria and eGFR decline in IgA nephropathy cohort
Tiny Footprints Predict Kidney Disease Progression
A single-center observational cohort of 37 patients with glomerulonephritis found that high-resolution podocyte morphometrics correlated wit…
Tiny changes in kidney cell shapes now predict disease progression better than standard tests, offering earlier warnings for patients with I…
Hispanic/Latinx adults with IgAN show rapid eGFR decline and high kidney event rates in retrospective cohort
Study describes kidney disease progression in Hispanic adults with IgA nephropathy
A retrospective case series of 259 Hispanic/Latinx adults with biopsy-proven IgAN in a U.S.
Hispanic adults with IgA nephropathy face a rapid kidney function decline, with nearly one-third losing over 5 ml/min annually and reaching …
Swiss IgAN cohort shows 43% ESKD progression, high immunosuppressive use over 8-year follow-up
What happens to IgA nephropathy patients over time? A Swiss study followed 158 people
A retrospective cohort analysis of 158 adult biopsy-proven IgAN patients at a Swiss tertiary center found 43.0% progressed to ESKD over medi…
A Swiss study of 158 IgA nephropathy patients found that 43% progressed to kidney failure requiring dialysis or a transplant within about ei…
Lactate dehydrogenase-to-albumin ratio studied in Chinese patients with IgA nephropathy
Study explores blood marker for predicting kidney disease progression in Chinese patients
A retrospective cohort study of 1,276 Chinese patients with biopsy-proven IgA nephropathy examined the lactate dehydrogenase-to-albumin rati…
A new blood test measuring inflammation and nutrition levels helps predict how kidney disease will progress in Chinese patients.
Questions about Membranous Nephropathy
What Traditional Chinese Botanical Medicine treats membranous nephropathy?
Traditional Chinese Botanical Medicine (CHMs) are being studied as a complementary option for membranous nephropathy because they can modulate immune pathways and reduce inflammation, though more clinical data is needed.
Full answer →